BHCM
RIGL icon

Brevan Howard Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Brevan Howard Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$353K Sell
13,071
-2,471
-16% -$83K ﹤0.01% 1521
2025
Q4 		$666K Buy
+15,542
New +$586K 0.01% 956
2024
Q1 		– Sell
-1,037
Closed -$15K – 1299
2023
Q4 		$15K Buy
+1,037
New +$10.6K ﹤0.01% 1006

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brevan Howard Capital Management's RIGL Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Rigel Pharmaceuticals (RIGL) stake by 16% in Q1 2026, selling an estimated $83K and leaving 13,071 shares worth $353K. The position accounts for ﹤0.01% of the portfolio, ranked #1521.

Brevan Howard Capital Management first reported a position in RIGL in Q4 2023 and has held it in 3 quarters since. The position peaked at $666K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Brevan Howard Capital Management held 13,071 shares of Rigel Pharmaceuticals worth $353K as of Q1 2026.
  • Brevan Howard Capital Management sold 2,471 Rigel Pharmaceuticals shares in Q1 2026, an estimated $83K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1521 holding.
  • Brevan Howard Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2023 and has held it in 3 quarters since.
  • Brevan Howard Capital Management's Rigel Pharmaceuticals position peaked at $666K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.